Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Chest MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cystic fibrosis.Lancet. 2021; 397: 2195-2211
- Structure, gating, and regulation of the CFTR anion channel.Physiol Rev. 2019; 99: 707-738
- The molecular evolution of function in the CFTR chloride channel.J Gen Physiol. 2021; 153: e202012625
- Origins of cystic fibrosis lung disease.N Engl J Med. 2015; 372: 351-362
- A developmental role of the cystic fibrosis transmembrane conductance regulator in cystic fibrosis lung disease pathogenesis.Front Cell Dev Biol. 2021; 9: 742891
- Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications.Am J Respir Crit Care Med. 2020; 201: 1193-1208
- Personalised medicine for cystic fibrosis: treating the basic defect.Eur Respir Rev. 2013; 22: 3-5
- Targeted therapies to improve CFTR function in cystic fibrosis.Genome Med. 2015; 7: 101
- Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770.Proc Natl Acad Sci U S A. 2009; 106: 18825-18830
- A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.N Engl J Med. 2011; 365: 1663-1672
- Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.N Engl J Med. 2010; 363: 1991-2003
- Physiology of the sweat gland in cystic fibrosis of the pancreas.Pediatrics. 1956; 18: 701-715
- Cystic fibrosis Foundation patient registry 2020 Annual data Report. Cystic Fibrosis Foundation, Bethesda, MD2021
- The DeltaF508 mutation causes CFTR misprocessing and cystic fibrosis-like disease in pigs.Sci Transl Med. 2011; 3 (74ra24)
- Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction.Chem Biol. 2013; 20: 943-955
- Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809.Proc Natl Acad Sci U S A. 2011; 108: 18843-18848
- Novel picolinamide-based cystic fibrosis transmembrane regulator modulators: evaluation of WO2013038373, WO2013038376, WO2013038381, WO2013038386 and WO2013038390.Expert Opin Ther Pat. 2014; 24: 829-837
- A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.Lancet Respir Med. 2014; 2: 527-538
- Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR.N Engl J Med. 2015; 373: 220-231
- Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del.N Engl J Med. 2017; 377: 2013-2023
- Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.Lancet. 2019; 394: 1940-1948
- Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele.N Engl J Med. 2019; 381: 1809-1819
- Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease.Respir Med Res. 2021; 80: 100829
- Rapid improvement after starting elexacaftor-tezacaftor- ivacaftor in patients with cystic fibrosis and advanced pulmonary disease.Am J Respir Crit Care Med. 2021; 204: 64-73
- Effect of highly effective modulator therapy on quality of life in adults with cystic fibrosis.Int Forum Allergy Rhinol. 2021; 11: 75-78
- Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world - opportunities and challenges.Curr Opin Pulm Med. 2021; 27: 554-566
- Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.Am J Respir Crit Care Med. 2014; 190: 175-184
- Ivacaftor-induced sweat chloride reductions correlate with increases in airway surface liquid pH in cystic fibrosis.JCI insight. 2018; 3: e121468
- Mucus obstruction and inflammation in early cystic fibrosis lung disease: emerging role of the IL-1 signaling pathway.Pediatr Pulmonol. 2019; 54: S5-S12
- Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis.Sci Transl Med. 2019; 11
- Animal and model systems for studying cystic fibrosis.J Cyst Fibros. 2018; 17: S28-S34
- Infection is not required for mucoinflammatory lung disease in CFTR-knockout ferrets.Am J Respir Crit Care Med. 2018; 197: 1308-1318
- Early lung disease exhibits bacteria-dependent and -independent abnormalities in cystic fibrosis pigs.Am J Respir Crit Care Med. 2021; 204: 692-702
- Emerging concepts and therapies for mucoobstructive lung disease.Ann Am Thorac Soc. 2018; 15: S216-S226
- Airway mucus obstruction triggers macrophage activation and matrix metalloproteinase 12-dependent emphysema.Am J Respir Cell Mol Biol. 2014; 51: 709-720
- Regulatory T-cell impairment in cystic fibrosis patients with chronic pseudomonas infection.Am J Respir Crit Care Med. 2015; 191: 914-923
- Cystic fibrosis transmembrane conductance regulator (CFTR) in human lung microvascular endothelial cells controls oxidative stress, reactive oxygen-mediated cell signaling and inflammatory responses.Front Physiol. 2020; 11: 879
- Altered respiratory epithelial cell cytokine production in cystic fibrosis.J Allergy Clin Immunol. 1999; 104: 72-78
- Exaggerated activation of nuclear factor-kappaB and altered IkappaB-beta processing in cystic fibrosis bronchial epithelial cells.Am J Respir Cell Mol Biol. 2000; 23: 396-403
- CFTR inhibition mimics the cystic fibrosis inflammatory profile.Am J Physiol Lung Cell Mol Physiol. 2007; 292: L383-L395
- Cystic fibrosis: a mucosal immunodeficiency syndrome.Nat Med. 2012; 18: 509-519
- Divergence of bacterial communities in the lower airways of CF patients in early childhood.PloS One. 2021; 16: e0257838
- Differences in the lower airway microbiota of infants with and without cystic fibrosis.J Cystic Fibrosis. 2019; 18: 646-652
- Opportunistic infections in lung disease: Pseudomonas infections in cystic fibrosis.Curr Opin Pharmacol. 2007; 7: 244-251
- Clinical significance of microbial infection and adaptation in cystic fibrosis.Clin Microbiol Rev. 2011; 24: 29-70
- Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa.Am J Respir Crit Care Med. 2004; 169: 811-815
- Initial acquisition and succession of the cystic fibrosis lung microbiome is associated with disease progression in infants and preschool children.PLoS Pathog. 2018; 14: e1006798
- Lung microbiota across age and disease stage in cystic fibrosis.Sci Rep. 2015; 5: 10241
- Decade-long bacterial community dynamics in cystic fibrosis airways.Proc Natl Acad Sci U S A. 2012; 109: 5809-5814
- Relationship between airway dysbiosis, inflammation and lung function in adults with cystic fibrosis.J Cystic Fibrosis. 2021; 20: 754-760
- Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation.Thorax. 2013; 68: 532-539
- Sputum biomarkers and the prediction of clinical outcomes in patients with cystic fibrosis.PloS One. 2012; 7: e42748
- The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation.Pediatr Pulmonol. 2007; 42: 729-735
- Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis.Am J Respir Crit Care Med. 2003; 168: 1471-1475
- Association of antibiotics, airway microbiome, and inflammation in infants with cystic fibrosis.Ann Am Thorac Soc. 2017; 14: 1548-1555
- Innate and adaptive immunity in cystic fibrosis.Clin chest Med. 2016; 37: 17-29
- Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes.Clin Exp Immunol. 2000; 120: 518-525
- Strong toll-like receptor responses in cystic fibrosis patients are associated with higher lung function.J Cystic Fibrosis. 2020; 19: 608-613
- Pulmonary T(H)2 response in Pseudomonas aeruginosa- infected patients with cystic fibrosis.J Allergy Clin Immunol. 2006; 117: 204-211
- Alveolar macrophages and CC chemokines are increased in children with cystic fibrosis.Eur Respir J. 2009; 34: 655-661
- Increased platelet activation occurs in cystic fibrosis patients and correlates to clinical status.Thromb Res. 2018; 162: 32-37
- Dysregulated signalling pathways in innate immune cells with cystic fibrosis mutations.Cell Mol Life Sci. 2020; 77: 4485-4503
- Neutrophil-mediated phagocytic host defense defect in myeloid Cftr-inactivated mice.PloS One. 2014; 9: e106813
- Role of CFTR expressed by neutrophils in modulating acute lung inflammation and injury in mice.Inflamm Res. 2011; 60: 619-632
- Cystic fibrosis lung immunity: the role of the macrophage.J Innate Immun. 2016; 8: 550-563
- CFTR is a negative regulator of gamma delta T cell IFN-gamma production and antitumor immunity.Cell Mol Immunol. 2021; 18: 1934-1944
- Lung immunoglobulin A immunity dysregulation in cystic fibrosis.EBioMedicine. 2020; 60: 102974
- CFTR regulates B cell activation and lymphoid follicle development.Respir Res. 2019; 20: 133
- Influence of the cystic fibrosis transmembrane conductance regulator on expression of lipid metabolism-related genes in dendritic cells.Respir Res. 2009; 10: 26
- Cystic fibrosis transmembrane conductance regulator dysfunction in platelets drives lung hyperinflammation.J Clin Invest. 2020; 130: 2041-2053
- Ivacaftor partially corrects airway inflammation in a humanized G551D rat.Am J Physiol Lung Cell Mol Physiol. 2021; 320: L1093-L1100
- Absence of the cystic fibrosis transmembrane regulator (Cftr) from myeloid-derived cells slows resolution of inflammation and infection.J Leukoc Biol. 2012; 92: 1111-1122
- Macrophages directly contribute to the exaggerated inflammatory response in cystic fibrosis transmembrane conductance regulator-/- mice.Am J Respir Cell Mol Biol. 2009; 40: 295-304
- The distribution and role of the CFTR protein in the intracellular compartments.Membranes (Basel). 2021; 11
- Cystic fibrosis transmembrane conductance regulator recruitment to phagosomes in neutrophils.J innate Immun. 2013; 5: 219-230
- New insights into cystic fibrosis: molecular switches that regulate CFTR.Nat Rev Mol Cell Biol. 2006; 7: 426-436
- Reduced caveolin-1 promotes hyperinflammation due to abnormal heme oxygenase-1 localization in lipopolysaccharide-challenged macrophages with dysfunctional cystic fibrosis transmembrane conductance regulator.J Immunol. 2013; 190: 5196-5206
- CFTR: a hub for kinases and crosstalk of cAMP and Ca2+.FEBS J. 2013; 280: 4417-4429
- Targeting the heme oxygenase 1/carbon monoxide pathway to resolve lung hyper-inflammation and restore a regulated immune response in cystic fibrosis.Front Pharmacol. 2020; 11: 1059
- Metabolic signatures of cystic fibrosis identified in dried blood spots for newborn screening without carrier identification.J Proteome Res. 2019; 18: 841-854
- Cystic fibrosis. Carbohydrate metabolism in CF and in animal models for CF.Acta Paediatr Scand Suppl. 1987; 332: 1-30
- Increased activity of four glycolytic enzymes in cultured fibroblasts from cystic fibrosis patients.Res Commun Chem Pathol Pharmacol. 1986; 51: 405-408
- Glycolysis - a key player in the inflammatory response.FEBS J. 2020; 287: 3350-3369
- Metabolic reprogramming in macrophages and dendritic cells in innate immunity.Cell Res. 2015; 25: 771-784
- Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis.Thorax. 2001; 56: 306-311
- A flow cytometric method for isolating cystic fibrosis airway macrophages from expectorated sputum.Am J Respir Cell Mol Biol. 2019; 61: 42-50
- Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages.Cell. 2016; 167: 457-470.e3
- CFTR-PTEN-dependent mitochondrial metabolic dysfunction promotes Pseudomonas aeruginosa airway infection.Sci Transl Med. 2019; 11: eaav4634
- Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition.Nat Cell Biol. 2010; 12: 863-875
- Cystic fibrosis transmembrane conductance regulator attaches tumor suppressor PTEN to the membrane and promotes anti Pseudomonas aeruginosa immunity.Immunity. 2017; 47: 1169-1181.e7
- IL-1 receptor antagonist ameliorates inflammasome- dependent inflammation in murine and human cystic fibrosis.Nat Commun. 2016; 7: 10791
- Metabolic instruction of immunity.Cell. 2017; 169: 570-586
- Exaggerated inflammatory responses mediated by Burkholderia cenocepacia in human macrophages derived from Cystic fibrosis patients.Biochem Biophys Res Commun. 2012; 424: 221-227
- Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis.Am J Respir Cell Mol Biol. 2009; 41: 590-602
- ENaC-mediated sodium influx exacerbates NLRP3-dependent inflammation in cystic fibrosis.Elife. 2019; 8: e49248
- Metabolic reprograming of cystic fibrosis macrophages via the IRE1alpha arm of the unfolded protein response results in exacerbated inflammation.Front Immunol. 2019; 10: 1789
- Role of endoplasmic reticulum stress in cystic fibrosis-related airway inflammatory responses.Proc Am Thorac Soc. 2010; 7: 387-394
- Role of IRE1alpha/XBP-1 in cystic fibrosis airway inflammation.Int J Mol Sci. 2017; 18: 118
- Small macrophages are present in early childhood respiratory disease.J Cyst Fibros. 2012; 11: 201-208
- Single-cell transcriptional archetypes of airway inflammation in cystic fibrosis.Am J Respir Crit Care Med. 2020; 202: 1419-1429
- Pivotal advance: expansion of small sputum macrophages in CF: failure to express MARCO and mannose receptors.J Leukoc Biol. 2009; 86 (Pubmed Exact): 479-489
- Distinct patterns of inflammation in the airway lumen and bronchial mucosa of children with cystic fibrosis.Thorax. 2012; 67: 164-170
- Abnormal trafficking and degradation of TLR4 underlie the elevated inflammatory response in cystic fibrosis.J Immunol. 2011; 186: 6990-6998
- Potent phagocytic activity with impaired antigen presentation identifying lipopolysaccharide-tolerant human monocytes: demonstration in isolated monocytes from cystic fibrosis patients.J Immunol. 2009; 182: 6494-6507
- Monocytes from cystic fibrosis patients are locked in an LPS tolerance state: down-regulation of TREM-1 as putative underlying mechanism.PloS one. 2008; 3: e2667
- Cystic fibrosis plasma blunts the immune response to bacterial infection.Am J Respir Cell Mol Biol. 2019; 61: 301-311
- Translocated LPS might cause endotoxin tolerance in circulating monocytes of cystic fibrosis patients.PloS One. 2011; 6: e29577
- Endotoxin tolerance: new mechanisms, molecules and clinical significance.Trends Immunol. 2009; 30: 475-487
- Higher plasma endothelial markers in adults with cystic fibrosis compared with healthy age-matched control subjects.Ann Am Thorac Soc. 2019; 16: 768-771
- Mutations of cystic fibrosis transmembrane conductance regulator (CFTR) gene cause a monocyte-selective adhesion deficiency.Am J Respir Crit Care Med. 2016; 193: 1123-1133
- Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa.Am J Physiol Lung Cell Mol Physiol. 2018; 314: L432-L438
- Inflammatory response in airway epithelial cells isolated from patients with cystic fibrosis.Am J Respir Crit Care Med. 2002; 166: 1248-1256
- Vx-809/Vx-770 treatment reduces inflammatory response to Pseudomonas aeruginosa in primary differentiated cystic fibrosis bronchial epithelial cells.Am J Physiol Lung Cell Mol Physiol. 2018; 314: L635-L641
- CFTR rescue with VX-809 and VX-770 favors the repair of primary airway epithelial cell cultures from patients with class II mutations in the presence of Pseudomonas aeruginosa exoproducts.J Cyst Fibros. 2018; 17: 705-714
- Airway epithelial inflammation in vitro augments the rescue of mutant CFTR by current CFTR modulator therapies.Front Pharmacol. 2021; 12: 628722
- Inflammatory cytokines TNF-alpha and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators.J Clin Invest. 2021; 131: e150398
- Phenotypes of CF rabbits generated by CRISPR/Cas9- mediated disruption of the CFTR gene.JCI insight. 2021; 6: e139813
- Ivacaftor reverses airway mucus abnormalities in a rat model harboring a humanized G551D-CFTR.Am J Respir Crit Care Med. 2020; 202: 1271-1282
- In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis.Sci Transl Med. 2019; 11: eaau7531
- Poster Session, poster #447: development of a G551D porcine model of cystic fibrosis.Pediatr Pulmonol. 2019; 54: S155-S480
- Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.Clin Infect Dis. 2015; 60: 703-712
- Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor.Thorax. 2018; 73: 731-740
- Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor.Pediatr Pulmonol. 2019; 54: 1200-1208
- Changes in airway microbiome and inflammation with ivacaftor treatment in patients with cystic fibrosis and the G551D mutation.Ann Am Thorac Soc. 2020; 17: 212-220
- Ivacaftor, a cystic fibrosis transmembrane conductance regulator potentiator, enhances ciprofloxacin activity against Pseudomonas aeruginosa.Am J Rhinol Allergy. 2019; 33: 129-136
- Antibacterial properties of the CFTR potentiator ivacaftor.J Cyst Fibros. 2014; 13: 515-519
- The impact of CFTR modulator therapies on CF airway microbiology.J Cyst Fibros. 2020; 19: 359-364
- Activity of innate antimicrobial peptides and ivacaftor against clinical cystic fibrosis respiratory pathogens.Int J Antimicrob Agents. 2017; 50: 427-435
- Extended-culture and culture-independent molecular analysis of the airway microbiota in cystic fibrosis following CFTR modulation with ivacaftor.J Cyst Fibros. 2021; 20: 747-753
- CORK study in cystic fibrosis: sustained improvements in Ultra-low-dose chest CT scores after CFTR modulation with ivacaftor.Chest. 2018; 153: 395-403
- Changes in the cystic fibrosis airway microbiome in response to CFTR modulator therapy.Front Cell Infect Microbiol. 2021; 11: 548613
- Restoring CFTR function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections.Am J Respir Crit Care Med. 2017; 195: 1617-1628
- Antibiotic exposure and interpersonal variance mask the effect of ivacaftor on respiratory microbiota composition.J Cyst Fibros. 2018; 17: 50-56
- Lung clearance index: evidence for use in clinical trials in cystic fibrosis.J Cyst Fibros. 2014; 13: 123-138
- Multiple breath washout outcomes are sensitive to inflammation and infection in children with cystic fibrosis.Ann Am Thorac Soc. 2017; 14: 1436-1442
- Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.Lancet Respir Med. 2013; 1: 630-638
- Peripheral lung effect of elexacaftor/tezacaftor/ivacaftor in adult cystic fibrosis.J Cyst Fibros. 2022; 21: 160-163
- Computed tomography correlates with pulmonary exacerbations in children with cystic fibrosis.Am J Respir Crit Care Med. 2005; 172: 1128-1132
- Chest computed tomography predicts the frequency of pulmonary exacerbations in children with cystic fibrosis.Ann Am Thorac Soc. 2015; 12: 64-69
- Magnetic resonance imaging of cystic fibrosis: multi-organ imaging in the age of CFTR modulator therapies.J Cyst Fibros. 2021; 21: e148-e157
- Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor.Eur Respir J. 2016; 48: 249-252
- Cystic fibrosis disease modifiers: complex genetics defines the phenotypic diversity in a monogenic disease.Annu Rev Genomics Hum Genet. 2018; 19: 201-222
- Cystic fibrosis lung disease modifiers and their relevance in the new era of precision medicine.Genes (Basel). 2021; 12: 562
- Mapping targetable inflammation and outcomes with cystic fibrosis biomarkers.Pediatr Pulmonol. 2017; 52: S21-S28
- Designing clinical trials for anti-inflammatory therapies in cystic fibrosis.Front Pharmacol. 2020; 11: 576293
- Association between pulmonary function and sputum biomarkers in cystic fibrosis.Am J Respir Crit Care Med. 2007; 175: 822-828
- Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis.Am J Respir Crit Care Med. 2012; 186: 857-865
- SPLUNC1: a novel marker of cystic fibrosis exacerbations.Eur Respir J. 2021; 58: 2000507
- Ivacaftor reduces inflammatory mediators in upper airway lining fluid from cystic fibrosis patients with a G551D mutation: serial non-invasive home-based collection of upper airway lining fluid.Front Immunol. 2021; 12: 642180
- Increased inflammatory markers detected in nasal lavage correlate with paranasal sinus abnormalities at MRI in adolescent patients with cystic fibrosis.Antioxidants (Basel). 2021; 10: 1412
- Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function.Sci Rep. 2018; 8: 17066
- Delayed neutrophil apoptosis enhances NET formation in cystic fibrosis.Thorax. 2018; 73: 134-144
- Trikafta rescues CFTR and lowers monocyte P2X7R-induced inflammasome activation in cystic fibrosis.Am J Respir Crit Care Med. 2022; 205: 783-794
- Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis.Elife. 2020; 9: e54556
- Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor.J Cyst Fibros. 2015; 15: 67-73
- Ivacaftor-induced proteomic changes suggest monocyte defects may contribute to the pathogenesis of cystic fibrosis.Am J Respir Cell Mol Biol. 2016; 54: 594-597
- Ivacaftor decreases monocyte sensitivity to interferon-gamma in people with cystic fibrosis.ERJ Open Res. 2020; 6
- Transcriptomic responses to ivacaftor and prediction of ivacaftor clinical responsiveness.Am J Respir Cell Mol Biol. 2019; 61: 643-652
- CFTR modulator therapy enhances peripheral blood monocyte contributions to immune responses in people with cystic fibrosis.Front Pharmacol. 2020; 11: 1219
- Updates on T helper type 17 immunity in respiratory disease.Immunology. 2019; 156: 3-8
- High peripheral blood th17 percent associated with poor lung function in cystic fibrosis.PloS One. 2015; 10: e0120912
- Pseudomonas aeruginosa infection, but not mono or dual-combination CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis.J Cyst Fibros. 2021; 20: 1072-1079
- Krebs cycle reborn in macrophage immunometabolism.Annu Rev Immunol. 2020; 38: 289-313
- Succinate is an inflammatory signal that induces IL- 1beta through HIF-1alpha.Nature. 2013; 496: 238-242
- Itaconate links inhibition of succinate dehydrogenase with macrophage metabolic remodeling and regulation of inflammation.Cell Metab. 2016; 24: 158-166
- Pseudomonas aeruginosa Utilizes host- derived itaconate to redirect its metabolism to promote biofilm formation.Cell Metab. 2020; 31: 1091-1106.e6
- Staphylococcus aureus induces an itaconate-dominated immunometabolic response that drives biofilm formation.Nat Commun. 2021; 12: 1399
- Origin and physiological roles of inflammation.Nature. 2008; 454: 428-435
- The extrapulmonary effects of cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis.Ann Am Thorac Soc. 2020; 17: 147-154
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
